Manuscripts

In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.

Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG; the Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):348-355. PMID: 21353964 [PubMed - as supplied by publisher]

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.

Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):342-347. PMID: 21353963 [PubMed - as supplied by publisher]

Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.

McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ, Zhanel GG, Mulvey MR; the Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):335-341. PMID: 21353962 [PubMed - as supplied by publisher]

Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ; the Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):326-334. PMID: 21353961[PubMed - as supplied by publisher]

Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study.

Nichol KA, Adam HJ, Hussain Z, Mulvey MR, McCracken M, Mataseje LF, Thompson K, Kost S, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):320-325. PMID: 21353960 [PubMed - as supplied by publisher]

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada-results of the CANWARD 2007-2009 study.

Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):314-319. PMID: 21353959 [PubMed - as supplied by publisher]

Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.

Adam HJ, Decorby M, Rennie R, Karlowsky JA, Hoban DJ, Zhanel GG; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):307-313. PMID: 21353958 [PubMed - as supplied by publisher]

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study.

Zhanel GG, Adam HJ, Low DE, Blondeau J, Decorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, Hoban DJ; The Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):291-306. PMID: 21353957 [PubMed - as supplied by publisher]

Introduction to the CANWARD Study (2007-2009).

Hoban DJ, Zhanel GG.

Diagn Microbiol Infect Dis. 2011 Mar;69(3):289-90. No abstract available. PMID: 21353956 [PubMed - in process]

Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagacé-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J; Canadian Antimicrobial Resistance Alliance, Hoban DJ.

ntimicrob Agents Chemother. 2010 Nov;54(11):4684-93. Epub 2010 Aug 30.PMID: 20805395 [PubMed - in process]

Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data.

Zelenitsky SA, Ariano RE, Zhanel GG.

J Antimicrob Chemother. 2010 Oct 5. [Epub ahead of print] PMID: 20926397 [PubMed - as supplied by publisher]

Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines.

Lynch JP 3rd, Zhanel GG.

Curr Opin Pulm Med. 2010 May;16(3):217-25.PMID: 20375783 [PubMed - in process]

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000.PMID: 20426497 [PubMed - in process]

Characterization of plasmids encoding CMY-2 AmpC beta-lactamases from Escherichia coli in Canadian intensive care units.

Baudry PJ, Mataseje L, Zhanel GG, Hoban DJ, Mulvey MR.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):379-83. Epub 2009 Sep 23.PMID: 19775846 [PubMed - indexed for MEDLINE]

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. Epub 2009 Sep 8.PMID: 19738018 [PubMed - indexed for MEDLINE]

In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.

Walkty A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2009 Nov;53(11):4924-6. Epub 2009 Aug 24.PMID: 19704135 [PubMed - indexed for MEDLINE]

Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.

Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA.

J Antimicrob Chemother. 2009 Oct;64(4):824-8. Epub 2009 Jul 29.PMID: 19643776 [PubMed - indexed for MEDLINE]

Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007.

McCracken M, DeCorby M, Fuller J, Loo V, Hoban DJ, Zhanel GG, Mulvey MR.

J Antimicrob Chemother. 2009 Sep;64(3):552-5. Epub 2009 Jul 3.PMID: 19578083 [PubMed - indexed for MEDLINE]

Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.

Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.

J Antimicrob Chemother. 2009 Aug;64(2):364-9. Epub 2009 May 19.PMID: 19454524 [PubMed - indexed for MEDLINE]

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagac´-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2009;69(7):809-31. doi: 10.2165/00003495-200969070-00003. Review.PMID: 19441869 [PubMed - indexed for MEDLINE]